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Abstract
Recent advances in genetic testing for heritable cardiac diseases have led to increasing 
involvement of the genetic counselor in cardiology practice. We present a series of cases collected 
from a nationwide query of genetics professionals regarding issues related to cost and utilization 
of genetic testing. Three themes emerged across cases: (1) choosing the most appropriate genetic 
test, (2) choosing the best person to test, and (3) interpreting results accurately. These cases 
demonstrate that involvement of a genetic counselor throughout the evaluation, diagnosis, and 
continuing management of individuals and families with inherited cardiovascular conditions helps 
to promote the efficient use of health care dollars.
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INTRODUCTION
In the past decade, cardiovascular genetic services have rapidly emerged at the forefront of 
what is now considered state of the art cardiology care. Improvements in the understanding 
of inherited cardiac conditions have been followed by a boom in the availability of 
cardiovascular genetic tests leading to changes in practice in both the cardiology and 
genetics fields. Cardiology and genetics sub-specialists ordering genetic testing have been 
called upon to make decisions about patient and test selection and to incorporate genetic 
information into care plans as needed. It has become evident over recent years that the 
financial impact of genetic tests both on the patient and the healthcare system is a relevant 
consideration when incorporating these services into patient care.
The need for integration of genetic medicine (often via a genetic counselor) into cardiology 
practice has been increasingly recognized as a benefit for patients and their families.1–10 
Genetic counselors help patients and their providing physicians understand the implications 
of complex genetic information for the care of the patient and, in some cases, their 
family1–4. The value of the genetic counseling process has been documented previously, 
often with regard to hereditary cancer syndromes10–21. One conclusion from many of these 
publications is that the medical genetics and psychosocial counseling expertise of the 
genetic counselor in the application of genetic testing in clinical care positively impacts the 
use of healthcare dollars and adds value to patient care.
We present a series of cases that reveal specific issues related to appropriate genetic test 
utilization. These issues can be avoided or diminished by inclusion of a genetic counselor in 
the care of patients undergoing genetic risk evaluation and testing for hereditary cardiac 
diseases. In particular, these cases illustrate opportunities for health care savings through 
collaboration with a genetic counselor whose skill set facilitates the integration of the most 
appropriate genetic testing options (Table 1). The patient process is diagramed in Figure 1 
which highlights specific points in patient care at which a genetic counselor can impact 
genetic testing decisions and utilization. Three themes emerge in these cases: (1) choosing 
the most appropriate genetic test, (2) choosing the best person to test, and (3) interpreting 
results accurately.
Genetic Evaluations for Inherited Cardiovascular Conditions
Examples of common indications for referral for genetic counseling and genetic testing are 
listed in Table 2. There are some generalities that can be made about inherited risks for 
cardiovascular disease that are important for understanding the impact of the cases 
described. Specific pathology, diagnosis, genetic etiology, and management have been 
extensively reviewed by others22–30 and will not be reviewed in detail.
• Inherited cardiovascular diseases are associated with an increased risk for sudden 
cardiac death.
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• Identification of inherited monogenic cardiovascular disease in a patient typically 
confers a 50% risk for immediate relatives to be predisposed to the same disease.
• Variable expressivity, in which clinical signs and symptoms vary among family 
members, and incomplete penetrance, in which some mutation-positive individuals 
may never develop disease, frequently complicate risk prediction for family 
members.
• Life-long periodic cardiac evaluations are typically recommended for at-risk family 
members.
• The likelihood of identifying a mutation varies across conditions and is dependent 
on which family member undergoes genetic testing.
• If a mutation has been identified in a family, genetic testing can frequently 
determine which family members are predisposed to the condition and which are 
not.
• Genetic testing can often be inconclusive because testing may identify rare genetic 
variants that may not be related to the inherited disease in the family.
METHODS
Cases were solicited through a nationwide query of genetic counselors involved in clinical 
cardiovascular genetics practice. Cases were then selected by group consensus. The seven 
cases presented in this series are representative of recurrent themes where steps taken by the 
genetic counselor reduced excessive and inefficient testing choices, resulting in significant 
health care savings. The monetary values listed in this document are general figures based 
on the listed cost of laboratory testing at the time the manuscript was written.
CASES
Choosing the Most Appropriate Genetic Test—Choosing the most appropriate 
genetic testing strategy results in both the efficient use of healthcare dollars and the ability to 
answer the clinical question at hand. The process of selecting a genetic test is complicated 
by the number of genes associated with inherited cardiovascular conditions, increased 
number of labs offering testing, and the emergence of gene panels that include testing for 
many genes at once. Most inherited cardiovascular conditions exhibit genetic heterogeneity, 
whereby mutations in different genes, or different mutations in the same gene, can lead to 
the same disease. Mutations within a given gene may also confer differing phenotypes (i.e. 
dilated vs. hypertrophic cardiomyopathy).
Case 1: A 30-year-old man with a family history of Brugada Syndrome (BrS) sought 
genetic testing to determine whether he inherited the predisposition to BrS. A mutation in 
SCN5A had previously been identified in the patient’s brother who has BrS. In such cases, a 
genetic counselor would typically offer the at-risk relative genetic testing for the familial 
SCN5A mutation, typically at a cost of $350–$900, as well as help identify other at-risk 
family members who are candidates for genetic counseling and consideration of genetic 
testing. In fact, in the absence of the involvement of a genetic counselor, the patient 
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underwent genetic testing through two multi-gene panels: one for BrS, and one for LQTS. 
Both panels include the SCN5A gene and were able to assess that the patient had in fact 
inherited his brother’s mutation. However, the patient was also tested for many genes that 
were not clinically relevant. The two panel testing strategy cost over $10,000 incurring over 
$9,000 in unnecessary costs.
Case 2: A 14-year-old male experienced a cardiac arrest of unknown etiology. During 
hospitalization prior to the patient’s death, genetic testing was ordered to assess possible 
genetic etiologies. The tests ordered included three separate multi-gene panels: Long QT 
syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and 
arrhythmogenic right ventricular cardiomyopathy (ARVC), which together cover more than 
20 genes for a total cost of over $15,000. In spite of this extensive and expensive testing, a 
specific genetic cause for the boy’s cardiac arrest was not identified. The family was later 
referred to a genetic counselor who was able to help the family understand the implications 
of the patient’s unexplained arrest in the setting of the family history and negative genetic 
test results, and provide supportive counseling. In reviewing the patient’s testing history, the 
genetic counselor noted that a single multi-condition panel could have been ordered for 
approximately $5,000, saving $10,000 from the prior order; this test would have included all 
of the genes ordered on the three separate panels, plus several dozen other genes associated 
with cardiac arrest.
Case 3: A 67-year-old woman with a history of a type A aortic dissection presented for 
follow up with her managing physician. She had previously been evaluated by a genetic 
counselor and a geneticist as her family history was significant for a 6’8” son who died of a 
type A dissection at the age 39 years, and a father who had been diagnosed with a 
subclavian aneurysm at age 75 years. She had findings suggestive of a hereditary connective 
tissue disorder and had normal sequencing of FBN1 (Marfan syndrome), as well as TGFBR1 
and TGFBR2 (Loeys Dietz syndrome). At the time of a re-evaluation by the genetics team, 
additional testing for a newly described genetic cause of familial aneurysms and dissections, 
SMAD3 (Aneurysm Osteoarthritis syndrome), was recommended by the genetic counselor. 
Although the referring provider originally misinterpreted the recommendation for SMAD3 
testing and repeated the FBN1, TGFBR1 and TGFBR2 analysis, the genetic counselor 
identified and canceled the unnecessary duplicate testing and coordinated the SMAD3 
testing. The SMAD3 testing identified a mutation responsible for the family’s vascular 
presentation. The involvement of the genetic counselor allowed for recognition of and 
testing for this newly described condition, as well as prevented over $2000 worth of 
duplicate and unnecessary testing. With the identification of a specific mutation, the genetic 
diagnosis was established and genetic testing was subsequently available for family 
members.
KEY POINT
Involvement of a genetic counselor can help reduce unnecessary healthcare costs by 
making sure the most appropriate testing is ordered.
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Choosing the Best Person to Test—Collecting and analyzing an in-depth, multi-
generational family history can impact genetic testing decisions and help identify the most 
pertinent person to test. This process will maximize the odds of an informative genetic test 
result and thereby improve post-test screening options and interventions for family 
members. Identifying this starting point requires careful consideration and must be tailored 
to each family. Ideally, the initial person tested should be the most significantly affected 
family member, the youngest affected family member, or the individual with additional 
extra-cardiac findings in the case of syndromic heart disease. Sometimes healthy individuals 
present to a cardiovascular genetics clinic due to a family history of sudden death. In these 
situations, the most appropriate individual to initiate genetic testing is often deceased, and 
post-mortem testing can only be done if a specimen appropriate for genetic testing is 
available.
In families where previous genetic testing identified a causal mutation, implementing testing 
in a cascade manner will be most efficient. Cascade testing involves testing family members 
one-at-a-time or in small groups based on their relational proximity to the affected proband, 
in order to minimize unnecessary tests. When an individual is genotype negative for a 
familial mutation, this also means their children and descendants are not at risk for the 
familial mutation.
Case 4: A 6-year-old girl presented to genetics clinic due to a family history of LQTS. A 
familial LQT2-causative mutation in KCNH2 had been identified in a distant maternal 
cousin (Figure 2). The patient and numerous family members had been undergoing 
cardiology evaluations annually since birth due to the family history. The patient and her 
mother had normal cardiology evaluations. Referral to the genetic counselor allowed for 
refinement of who within the family actually needed screening. The closest shared relative, 
the patient’s maternal grandmother, was living and not known to have LQTS. The genetic 
counselor advised the family that an optimal testing strategy would be to offer familial 
genetic testing to the patient’s grandmother. The cost of a single test for a known mutation is 
$350–900. The grandmother underwent genetic testing for the KCNH2 mutation; results 
revealed that the grandmother did not carry the familial mutation. Therefore, her eight 
children and grandchildren were not at increased risk for LQTS and would not need to 
continue to undergo related cardiology evaluations nor would they need genetic testing. 
Performing genetic testing on the grandmother as opposed to testing her eight children saved 
$2800–7200. Significant additional cost savings were realized from discontinuation of 
cardiovascular screening in the patient and other family members who were no longer 
considered at risk for the condition.
Case 5: A healthy 43-year-old female was referred to a cardiovascular genetics clinic for 
evaluation following her brother’s sudden death due to aortic dissection at age 51 (Figure 2). 
Her father also died suddenly of aortic dissection at age 53. No living family member, 
including the patient, had any aortic abnormalities detectable on imaging. The genetic 
counselor discussed with the family why it would be most informative for them to begin 
testing on a post-mortem specimen, however, no specimen suitable for genetic testing was 
available. Due to significant limitations in genetic testing for this clinical indication, testing 
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an unaffected family member would most likely yield an uninformative result that would not 
change recommendations for ongoing aortic imaging in the patient and other at-risk 
relatives. Instead of genetic testing, appropriate clinical screening recommendations were 
made to the family, promoting a more efficient use of healthcare dollars and avoiding the 
cost of uninformative genetic testing. Genetic tests for familial aortic disease range in cost 
from around $1800 to more than $5000, depending on the laboratory and number of genes 
included.
KEY POINT
Through pedigree analysis, a genetic counselor can help reduce costs and strengthen 
utility of genetic testing in a family by identifying the most appropriate individuals to test 
first.
Interpreting Results Accurately—In addition to the multifaceted logistics of ordering 
genetic tests, the interpretation of genetic test results can be complex. While a positive result 
(identification of a pathogenic mutation) can confirm a diagnosis and allow for familial 
genetic testing, a negative test result can be a challenge with regard to determining the next 
steps for the patient and family. Furthermore, variants of unknown significance (VUS) may 
be identified for which there is limited or insufficient evidence to draw conclusions about 
pathogenicity. While some VUS may eventually be reclassified as pathogenic mutations, 
many VUS may represent rare benign variations that are not the cause of familial disease. 
Since there is not enough information to make an accurate interpretation, a VUS should not 
be used to confirm or rule out an inherited condition.
Case 6: Following a young sudden death, the asymptomatic brother of the deceased 
underwent genetic testing for LQTS, which identified a variant that was reported as a 
“probable disease causing mutation” in an LQTS related gene. Clinical guidelines 
discourage offering unaffected relatives clinical testing for gene variants of uncertain 
significance for the purpose of medical management. However, in this case, it was assumed 
that the cause of the sudden death was LQTS and that the gene variant was pathogenic. 
Clinical evaluations and genetic testing for the presumed disease causing mutation were 
performed on over 20 additional relatives, many of whom were subsequently given LQTS 
diagnoses. Several family members then presented to a specialized multidisciplinary LQTS 
clinic that included a genetic counselor and were re-evaluated. A careful evaluation of 
clinical data (i.e. EKGs) and genetic testing results did not reveal a clinical correlation with 
the presumed disease causing mutation. Namely, individuals who carried this variant did not 
demonstrate a prolonged QT, casting doubt on the clinical significance of this variant. 
Reviewing the genetic test results in more detail, the genetic counselor noted that while the 
laboratory report indicated that the variant had been previously published in three unrelated 
probands with LQTS, the three published reports were in fact describing the same 
individual. Thus, the evidence for pathogenicity was weak and the variant was more 
appropriately classified as a VUS. Finally, a copy of the autopsy report from the deceased 
individual was obtained and reviewed. There were clear structural cardiac abnormalities that 
may well have contributed to the cause of death in the proband and were not consistent with 
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LQTS. Genetic testing for the 20 relatives was an avoidable cost of ~$350–900 each for a 
total of $7000–$18000. Some individuals also had implantable cardioverter defibrillators 
(ICDs) implanted based on the presence of the VUS. Implantation of one ICD may cost on 
the order of $20,000–35,00031, 32{Abriel, 2013 #1}. Additional potential costs associated 
with an ICD include absence from work, risks associated with surgical complications, as 
well as psychological stressors related to ICDs33, 34. This case highlights the importance of 
careful interpretation of genetic test results, the value of clinical correlation with mutation 
status, and the dangers of genetically testing asymptomatic family members for a VUS.
Case 7: A healthy 65-year-old woman presented to a genetic counselor with a family history 
of hypertrophic cardiomyopathy (HCM). A VUS in the MYBPC3 gene had been identified 
in her affected sister. Analysis of this large family’s history revealed a very strong family 
history of sudden death and unspecified heart problems. The patient had been undergoing 
screening for HCM for several years and did not have findings of the disease. She came to 
the genetic counseling session wishing to be tested for the sister’s VUS. The genetic 
counselor advised her that presymptomatic testing (using testing to assess risk of disease in 
healthy individuals) for a VUS is generally not recommended, since a positive or negative 
result would not be informative, and she would need to continue screening for HCM 
regardless of the genetic test result. At the end of the session, the patient planned to continue 
HCM screening every 3 to 5 years and genetic testing was not pursued.
Two years later, the genetic counselor identified literature that suggested the VUS detected 
in the sister was indeed a disease-causing mutation. The genetic counselor contacted the 
laboratory who had reported the sister’s VUS, and the laboratory re-classified the variant 
from VUS to pathogenic, allowing for informative presymptomatic testing in the family. 
The patient underwent genetic testing for the familial mutation and tested negative, 
eliminating the need for ongoing HCM screening for herself and confirming that her twelve 
children and fifteen grandchildren were not at risk for this mutation. Involvement of the 
genetic counselor in this case was critical for appropriate interpretation and use of a genetic 
test result over the span of several years. In this family, thousands of healthcare dollars have 
been saved by allowing presymptomatic testing to eliminate mutation-negative family 
members from the HCM screening protocol.
KEY POINT
Continued involvement of a genetic counselor facilitates up-to-date interpretation of 
genetic test results and can help to avoid unnecessary downstream costs.
DISCUSSION
Genetic testing is increasingly being incorporated into clinical care for individuals with 
inherited cardiovascular conditions. The inclusion of a genetic counselor in the care of 
patients with hereditary cardiovascular disease has been recommended in a number of 
consensus statements and practice guidelines1, 9, 23, 24, 35. Similarly, insurance companies 
are increasingly recognizing the value of a genetic counselor for appropriate utilization of 
genetic tests. Many insurers have adopted policies to help guide coverage decisions for 
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genetic testing. These policies often recommend, or in some cases require, genetic 
counseling provided by a genetic counselor for patients undergoing genetic testing for 
specific hereditary conditions, including Long QT syndrome. Cigna Medical Coverage 
Policy 0193 was one of the earliest, and it is reasonable to anticipate an increase in adoption 
of these policies by more insurance companies over time.
Several studies have demonstrated the cost-effectiveness of including genetic testing in 
cascade family screening for hypertrophic cardiomyopathy, inherited arrhythmia conditions, 
and familial hypercholesterolemia5, 6, 36–39. These analyses are dependent on the cost of the 
genetic test and the likelihood of identifying a mutation in the proband. Scenarios where the 
cost of testing is high, or testing is done in an individual with a low likelihood of identifying 
a mutation, would be less cost effective. However, when a familial mutation is defined, 
familial screening is possible and genetic testing becomes a cost-effective screening tool. 
This suggests that a careful approach to genetic testing is called for in order to maximize the 
cost-effectiveness of genetic testing in clinical practice.
Early involvement of a genetic counselor facilitates familial screening by helping to 
determine an etiology for disease. Appropriate pedigree analysis and risk assessment 
provide the basis for decisions about genetic testing. Case 3 highlights how knowledge of a 
newly available testing option provides a key opportunity to arrive at a specific genetic 
diagnosis. Once a familial mutation is known, other family members can undergo 
presymptomatic genetic testing to determine their risk of disease. Presymptomatic testing 
can determine which family members require ongoing cardiovascular surveillance and 
which ones do not. On average, half of at-risk family members will not have the familial 
mutation and thus will not require screening.
Expertise in choosing the most appropriate tests helps to prevent excessive costs related to 
genetic testing. For example, it is important to know when familial testing has already 
identified a specific gene mutation in a family so targeted testing can be performed and 
significant cost savings can be realized (illustrated in cases 1 and 4). In other situations, 
although genetic testing may be available, testing the person being seen in clinic that day 
may not be informative, and is not indicated, as in case 5 and 6. When it is determined that 
testing first in another family member would be more appropriate, a genetic counselor is a 
resource to help facilitate testing in that family member. Even in an urgent setting such as 
case 2, the genetic testing strategy can be streamlined to minimize costs and obtain the most 
useful information. In cases in which a person’s prognosis is dire and a genetic cause has not 
been identified, genetic counselors can also discuss DNA banking as an option to guarantee 
a sample is available for any new tests that may be developed in the future40.
Technological advances in molecular analysis are driving rapid expansion of cardiovascular 
genetic testing options. Large multi-gene test panels and whole exome sequencing are 
increasingly available for inherited cardiac conditions and may offer an economical 
approach. It is important to note, however, that the composition of panels, methods used, 
costs, and turn-around-time will vary. It is also important to recognize that the inclusion of 
more genes on a panel increases the likelihood of identifying a VUS, which is an 
inconclusive result and can be troubling for patients and providers. Genetic counselors are 
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aware of the most current test availability, as well as each test’s benefits and limitations, 
which is key to providing the most relevant genetic information to patients and their 
physicians.
It is important for clinical and molecular information to be interpreted together to provide 
the best care for the patient and their family. For example, the presence of a VUS in an 
unaffected individual should be considered with caution and must be correlated with clinical 
evaluations as illustrated by cases 6 and 7. Additional information gained from family 
history and evaluation of family members can help to clarify whether or not a VUS might be 
reclassified and considered useful for family testing on a clinical or research basis. 
Continued involvement of a genetic counselor, as in case 7, can help facilitate the ongoing 
process of providing the most current update of genetic information.
The presented cases demonstrate the importance of appropriate test selection and accurate 
result interpretation in the care of patients with inherited cardiovascular conditions. The 
inclusion of a genetic counselor as part of the multidisciplinary team throughout the 
evaluation, diagnosis, and continuing care of individuals who have an inherited 
cardiovascular condition results in high quality care and appropriate utilization of genetic 
testing that meets the clinical needs while optimizing use of healthcare dollars. The genetic 
counselor is the medical professional most able to navigate the testing process for maximum 
cost effectiveness.
ACKNOWLEDGEMENTS
The project described was supported in part by the Indiana University Health – Indiana University School of 
Medicine Strategic Research Initiative.
Source of Funding:
Michael J. Ackerman, MD, PhD, is a consultant for Boston Scientific, Gilead Sciences, Metronic, St. Jude Medical. 
MJA and Mayo Clinic receive royalties from Transgenomic with respect to their FAMILION-LQTS and 
FAMILION-CPVT genetic tests. Katie Spoonamore, MS, CGC, is supported by the Indiana University Health – 
Indiana University School of Medicine Strategic Research Initiative.
REFERENCES
1. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of 
genetic testing for the channelopathies and cardiomyopathies this document was developed as a 
partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association 
(EHRA). Heart Rhythm. 2011; 8:1308–1339. [PubMed: 21787999] Guidelines for genetic testing 
for channelopathies and cardiomyopathies.
2. Caleshu C, Day S, Rehm HL, et al. Use and interpretation of genetic tests in cardiovascular genetics. 
Heart. 2010; 96:1669–1675. [PubMed: 20937756] Case-based discussion of principles and 
approaches to best use of genetic testing in cardiovascular genetics.
3. Dunn KE, Caleshu C, Cirino AL, et al. A clinical approach to inherited hypertrophy: the use of 
family history in diagnosis, risk assessment, and management. Circ Cardiovasc Genet. 2013; 6:118–
131. [PubMed: 23424256] Assessment and description of family history assessment as dynamic, 
ongoing process relevant to cardiovascular genetics care.
4. Ingles J, Yeates L, Semsarian C. The emerging role of the cardiac genetic counselor. Heart Rhythm. 
2011; 8:1958–1962. [PubMed: 21767518] Extensive description of development of, current role, 
and ideal role of genetic counselor in cardiovascular genetics.
Arscott et al. Page 9
Cardiol Rev. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
5. Ingles J, McGaughran J, Scuffham PA, et al. A cost-effectiveness model of genetic testing for the 
evaluation of families with hypertrophic cardiomyopathy. Heart. 2012; 98:625–630. [PubMed: 
22128210] Assesses cost-effectiveness of including genetic screening for family members in 
comparison to clinical screening alone.
6. Perez MV, Kumarasamy NA, Owens DK, et al. Cost-effectiveness of genetic testing in family 
members of patients with long-QT syndrome. Circ Cardiovasc Qual Outcomes. 2011; 4:76–84. 
[PubMed: 21139095] Assesses cost-effectiveness of three strategies regarding a first degree relative 
of LQTS patient.
7. Sturm AC, Hershberger RE. Genetic testing in cardiovascular medicine: current landscape and 
future horizons. Curr Opin Cardiol. 2013; 28:317–325. [PubMed: 23571470] Review of current 
genetic testing options and guidance on incorporating genetics in to cardiovascular medicine.
8. Priori SG, Wilde AA, Horie M, et al. Executive summary: HRS/EHRA/APHRS expert consensus 
statement on the diagnosis and management of patients with inherited primary arrhythmia 
syndromes. Heart Rhythm. 2013; 10:e85–e108. [PubMed: 23916535] International consensus 
statement on diagnosis and management of patients with inherited primary arrhythmias.
9. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy--a Heart 
Failure Society of America practice guideline. J Card Fail. 2009; 15:83–97. [PubMed: 19254666] 
Heart Failure Society guidelines on use of genetics for various cardiomyopathy evaluations.
10. Judge DP. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA. 2009; 302:2471–
2476. [PubMed: 19996403] Demonstrates benefits of genetics in individual and family evaluation 
for cardiomyopathies.
11. Aktan-Collan K, Mecklin JP, de la Chapelle A, et al. Evaluation of a counselling protocol for 
predictive genetic testing for hereditary non-polyposis colorectal cancer. J Med Genet. 2000; 
37:108–113. [PubMed: 10662810] Concludes that inclusion of genetic counseling is considered 
useful and supportive by patients.
12. Balmana J, Sanz J, Bonfill X, et al. Genetic counseling program in familial breast cancer: analysis 
of its effectiveness, cost and cost-effectiveness ratio. Int J Cancer. 2004; 112:647–652. [PubMed: 
15382046] Suggests that genetic testing and screening is cost-effect for preventive medicine 
approach to inherited cancer conditions
13. Brierley KL, Campfield D, Ducaine W, et al. Errors in delivery of cancer genetics services: 
implications for practice. Conn Med. 2010; 74:413–423. [PubMed: 20806621] Discussion of 
errors leading to assessment of expectation that clinicians cover all genetic concepts and testing, 
suggests role for genetic counselors in this area.
14. Brierley KL, Blouch E, Cogswell W, et al. Adverse events in cancer genetic testing: medical, 
ethical, legal, and financial implications. Cancer J. 2012; 18:303–309. [PubMed: 22846730] Case 
series demonstrating impact of errors in genetic testing on cost effectiveness, liabilty, and patients 
and families.
15. Christie J, Quinn GP, Malo T, et al. Cognitive and psychological impact of BRCA genetic 
counseling in before and after definitive surgery breast cancer patients. Ann Surg Oncol. 2012; 
19:4003–4011. [PubMed: 22766984] Pre-test counseling improves understanding and decision-
making in patients.
16. Griffith GL, Edwards RT, Gray J. Cancer genetics services: a systematic review of the economic 
evidence and issues. Br J Cancer. 2004; 90:1697–1703. [PubMed: 15150621] Systematic review 
of economics of cancer genetic services. Shows cost-effectiveness of genetic testing.
17. Forrest LE, Burke J, Bacic S, et al. Increased genetic counseling support improves communication 
of genetic information in families. Genet Med. 2008; 10:167–172. [PubMed: 18344705] 
Concludes that genetic counseling for proband increases likelihood of at-risk family member 
contact for genetic services.
18. Meiser B, Halliday JL. What is the impact of genetic counselling in women at increased risk of 
developing hereditary breast cancer? A meta-analytic review. Soc Sci Med. 2002; 54:1463–1470. 
[PubMed: 12061481] Concludes that genetic counseling decreases patient anxiety and improves 
understanding of individual risk.
19. Mester JL, Schreiber AH, Moran RT. Genetic counselors: your partners in clinical practice. Cleve 
Clin J Med. 2012; 79:560–568. [PubMed: 22854435] Explains process of genetic counseling, and 
describes value of genetic counseling in caring for patients and families with inherited conditions.
Arscott et al. Page 10
Cardiol Rev. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
20. Miller CE, Krautscheid P, Baldwin EE, et al. Genetic counselor review of genetic test orders in a 
reference laboratory reduces unnecessary testing. Am J Med Genet A. 2014; 164A:1094–1101. 
[PubMed: 24665052] Describes how the utilization of genetic counselors in the laboratory reduces 
healthcare costs to multiple stakeholders.
21. Plon SE, Cooper HP, Parks B, et al. Genetic testing and cancer risk management recommendations 
by physicians for at-risk relatives. Genet Med. 2011; 13:148–154. [PubMed: 21224735] Impact of 
genetic testing results on decision-making. Utilization of genetics professionals increases efficacy.
22. Abriel H, Zaklyazminskaya EV. Cardiac channelopathies: genetic and molecular mechanisms. 
Gene. 2013; 517:1–11. [PubMed: 23266818] Channelopathy review.
23. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment 
of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 124:e783–
e831. [PubMed: 22068434] Guidelines for treatment of HCM including genetics.
24. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/
SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic 
Aortic Disease: a report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, 
American College of Radiology, American Stroke Association, Society of Cardiovascular 
Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of 
Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. 
Circulation. 2010; 121:e266–e369. [PubMed: 20233780] Guidelines for treatment of thoracic 
aortic disease including genetics.
25. Jacoby D, McKenna WJ. Genetics of inherited cardiomyopathy. Eur Heart J. 2012; 33:296–304. 
[PubMed: 21810862] 
26. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013; 381:242–255. [PubMed: 
22874472] 
27. Murray B. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a review of 
molecular and clinical literature. J Genet Couns. 2012; 21:494–504. [PubMed: 22426942] 
28. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the 
diagnosis and management of patients with inherited primary arrhythmia syndromes: document 
endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in 
June 2013. Heart Rhythm. 2013; 10:1932–1963. [PubMed: 24011539] Consensus statement on 
diagnosis and management of inherited arrhythmias, including genetics.
29. Schwartz PJ, Ackerman MJ, George AL Jr, et al. Impact of genetics on the clinical management of 
channelopathies. J Am Coll Cardiol. 2013; 62:169–180. [PubMed: 23684683] Discussion of best 
use of genetics in care for patients with cardiac channelopathies.
30. Teekakirikul P, Kelly MA, Rehm HL, et al. Inherited cardiomyopathies: molecular genetics and 
clinical genetic testing in the postgenomic era. J Mol Diagn. 2013; 15:158–170. [PubMed: 
23274168] Overview of genetics and diagnosis of inherited cardiomyopathies.
31. Groeneveld PW, Matta MA, Suh JJ, et al. Costs and quality-of-life effects of implantable 
cardioverter-defibrillators. Am J Cardiol. 2006; 98:1409–1415. [PubMed: 17134641] Systematic 
review of ICD and Quality of Life outcomes.
32. Hlatky MA, Mark DB. The high cost of implantable defibrillators. Eur Heart J. 2007; 28:388–391. 
[PubMed: 17032689] Commetary on the cost of ICDs and improving cost-effectiveness.
33. Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic 
device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014; 
35:1186–1194. [PubMed: 24347317] Assessment of ICD risks and their frequency.
34. Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT syndrome patients who receive 
an implantable cardioverter-defibrillator and what happens to them?: data from the European 
Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation. 
2010; 122:1272–1282. [PubMed: 20837891] Description of cohort of patients with LQTS 
receiving ICDs.
35. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of 
Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of 
the American College of Cardiology/American Heart Association Task Force and the European 
Arscott et al. Page 11
Cardiol Rev. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Society of Cardiology Committee for Practice Guidelines (writing committee to develop 
Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of 
Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association 
and the Heart Rhythm Society. Circulation. 2006; 114:e385–e484. [PubMed: 16935995] 
ACC/AHA guidelines regarding management of ventricular arrhythmias. Includes genetics.
36. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac 
channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009; 
2:6–15. [PubMed: 19808439] Assesses utility and cost-effectiveness of genetic testing for patients 
with inherited channelopathies.
37. Wordsworth S, Leal J, Blair E, et al. DNA testing for hypertrophic cardiomyopathy: a cost-
effectiveness model. Eur Heart J. 2010; 31:926–935. [PubMed: 20299350] Assesses cost-
effectivness of using genetic testing in diagnoses and management of HCM.
38. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening 
for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 
2011; 97:1175–1181. [PubMed: 21685482] Demonstrates that family genetic screening is cost 
effective in FH.
39. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic 
screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med. 2004; 
4:97–104. [PubMed: 15199439] Systematic genetic screening of FH families is cost-effective.
40. MacLeod HDE, Honeywell C, Rutberg J. Genetic Counselors: An Important Resource for Families 
Following a Young Sudden Cardiac Death. Academic Forensic Pathology. 2013; 3:183–190. 
Describes role of genetic counselor in cases of sudden cardiac death in a young person.
41. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and 
management of pediatric and adult patients: clinical guidance from the National Lipid Association 
Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5:S1–S8. [PubMed: 
21600525] National Lipid Association guidance includes discussion of genetic testing.
42. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary 
arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126:14S–
34S. [PubMed: 15249493] Guidelines for pulmonary arterial hypertension, including discussion of 
genetic testing and genetic counseling.
Arscott et al. Page 12
Cardiol Rev. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Integrating a genetic counselor into clinical care. Flow chart depicts referral through genetic 
counseling and evaluation, determination of testing (or not), result disclosure, to 
communication of information to family members and referring providers. White boxes 
indicate decision points related to genetic testing. The genetic counselor may coordinate 
testing for family members once a positive mutation is identified.
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Figure 2. 
Pedigree examples for case 4 (A), and case 5 (B). Arrow indicates individual presenting for 
genetic counseling (proband). Standard pedigree notation using circles for females and 
squares for males. Filled symbol represents affected individual. Diagonal line indicates 
individual is deceased.
Arscott et al. Page 14
Cardiol Rev. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Arscott et al. Page 15
Table 1
Genetic Counselor Roles in Clinical Care
Risk Assessment ▪ Collect detailed medical and family history
▪ Assess risk for inherited cardiovascular condition in patient/family
Education ▪ Describe features, risk factors, and genetics of inherited cardiac condition
▪ Discuss screening, prevention, and management options that may be available
Genetic testing ▪ Identify and coordinate appropriate genetic testing options
▪ Discuss the benefits and limitations of genetic tests
▪ Address concerns about cost, insurance coverage, and insurance discrimination
Result Interpretation ▪ Review literature and laboratory information to provide accurate, up-to-date information
▪ Collaborate with providers to apply genetic information to patient/family care
Result disclosure ▪ Explain genetic test result and implications for patient and family
▪ Provide written documentation for families and providers
Client-centered counseling ▪ Address patient and family concerns regarding condition
▪ Discuss implications for family planning and reproductive options when relevant
▪ Facilitate family communication about diagnosis and testing options
▪ Identify resources for additional support and information
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Table 2
Indications for Referral to a Cardiovascular Genetic Counselor
Condition suspected in patient or family
history: Genetictesting
available
Guidelines (references)
for: Genetic
testing yieldGenetic
Counseling
Genetic
Testing
◦ Unexplained sudden death, sudden infant death syndrome + /−a 1, 8 1, 8 ~5% (SIDS) – ~35% (SUD)
◦ Sudden cardiac arrest, and/or idiopathic ventricular 
fibrillation
Inherited Arrhythmias: 1, 8 1, 8
◦ Long QT syndrome + 70–80%
◦ Brugada syndrome + 20–30%
◦ Catecholaminergic polymorphic ventricular tachycardia + 60 –70%
◦ Short QT syndrome + unknown
◦ Progressive cardiac conduction disease +/− unknown
Cardiomyopathies: 1, 23 1, 23
◦ Hypertrophic cardiomyopathy + 30–50%
◦ Dilated cardiomyopathy (idiopathic or familial) + 30–40%
◦ Arrhythmogenic right ventricular dysplasia/cardiomyopathy + 30–50%
◦ Restrictive cardiomyopathy + unknown
◦ Left ventricular noncompaction cardiomyopathy + ~20%
Conditions affecting the aorta and other blood vessels: 24 24
◦ Familial or early onset thoracic aortic aneurysm and 
dissection
+ 4–15%
◦ Marfan syndrome + 75–90%
◦ Loeys-Dietz syndrome + ~85%
◦ Ehlers-Danlos syndrome (vascular and classic types) + vascular 95%/classic 50%
◦ Arterial tortuosity syndrome +
◦ Bicuspid aortic valve +/− unknown
Congenital heart disease +/−a Varies
Coronary artery disease, early-onset and/or familial −
◦ Familial hypercholesterolemia + 41 60–80%
Pulmonary arterial hypertension, idiopathic or familial + 42 42 25% simplex
75% familial
Known familial mutation for cardiovascular condition + 1, 8, 23, 24 1, 8, 23, 24
+ = available; +/− = available for limited or specific indications; − = not clinically available;
a
availability of testing depends on risk assessment and evaluation
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